Rep. Josh Gottheimer Sells AbbVie Inc. (NYSE:ABBV) Stock

Representative Josh Gottheimer (Democratic-New Jersey) recently sold shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on June 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on May 5th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of Lumentum (NASDAQ:LITE) on 5/22/2026.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 5/22/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 5/21/2026.
• Purchased $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 5/19/2026.
• Sold $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 5/15/2026.
• Purchased $1,001 – $15,000 in shares of Palo Alto Networks (NASDAQ:PANW) on 5/14/2026.
• Sold $1,001 – $15,000 in shares of Nestle (OTCMKTS:NSRGY) on 5/14/2026.
• Purchased $1,001 – $15,000 in shares of Sandisk (NASDAQ:SNDK) on 5/7/2026.
• Sold $1,001 – $15,000 in shares of Nestle (OTCMKTS:NSRGY) on 5/5/2026.

AbbVie Trading Up 3.5%

Shares of ABBV opened at $224.81 on Friday. The company has a market capitalization of $397.19 billion, a price-to-earnings ratio of 110.74, a PEG ratio of 0.66 and a beta of 0.32. The stock has a 50 day moving average of $209.43 and a 200 day moving average of $219.30. AbbVie Inc. has a 12 month low of $181.73 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.AbbVie’s revenue was up 12.4% on a year-over-year basis. During the same period last year, the business posted $2.46 earnings per share. As a group, equities research analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ABBV shares. UBS Group dropped their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. Evercore set a $235.00 price objective on AbbVie in a report on Friday, May 15th. William Blair reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective for the company in a report on Thursday, April 30th. Finally, Barclays began coverage on AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $253.43.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s ovarian cancer drug Elahere received a green light from the UK’s NHS, expanding access in a hard-to-treat cancer market and reinforcing the drug’s commercial potential. British drug-cost watchdog recommends use of AbbVie’s ovarian cancer therapy
• Positive Sentiment: AbbVie also won European approval for Aquipta as a migraine treatment, adding another approved indication and supporting future sales growth for its neurology franchise. AbbVie receives EC approval for Aquipta to treat migraine
• Positive Sentiment: Analyst-style coverage highlighted AbbVie as a “cheap stock” and a potentially undervalued name, which can support investor sentiment around the stock’s longer-term upside. 5 Best Cheap Stocks to Buy for Beginners
• Neutral Sentiment: AbbVie completed several study updates, including a real-world upadacitinib study in China and a bioavailability study for ABBV-932, which are supportive for the pipeline but not immediate commercial catalysts. AbbVie Completes Real World Upadacitinib Study in China AbbVie Advances ABBV-932 With Completed Bioavailability Study
• Negative Sentiment: AbbVie ended an early lung-cancer trial for ABBV-647, which slightly trims one oncology upside avenue, even though it does not change the broader growth story. AbbVie Ends Early Lung Cancer Trial for ABBV-647

Institutional Investors Weigh In On AbbVie

Several institutional investors have recently added to or reduced their stakes in the business. Evansbrook LLC lifted its holdings in AbbVie by 1.4% during the first quarter. Evansbrook LLC now owns 3,531 shares of the company’s stock valued at $768,000 after purchasing an additional 49 shares during the last quarter. Wealthquest Corp lifted its position in shares of AbbVie by 6.3% during the first quarter. Wealthquest Corp now owns 3,618 shares of the company’s stock worth $787,000 after acquiring an additional 214 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of AbbVie by 1.3% during the first quarter. Parallel Advisors LLC now owns 103,875 shares of the company’s stock worth $22,592,000 after acquiring an additional 1,290 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of AbbVie by 0.9% during the first quarter. NewEdge Advisors LLC now owns 632,140 shares of the company’s stock worth $137,483,000 after acquiring an additional 5,648 shares in the last quarter. Finally, Optiver Holding B.V. purchased a new stake in shares of AbbVie during the first quarter worth $530,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.